Skip to main content
Article thumbnail
Location of Repository

Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression1

By Robert J. Motzer, David M. Nanus, Et Al, Cancer Res, Contact The Aacr Publications, Robert J. Motzer, David M. Nanus, Howard I. Scher, Dean F. Bajorin, Victor Reuter, William P. Tong, Jacqueline Iversen, Carl Louison, Anthony P. Albino and George J. Bosl


Twenty-six patients with advanced renal cell carcinoma were treated with suramin administered by continuous infusion, with dosing deter mined by a nomogram. One patient achieved a partial response and five patients achieved a minor response or had stable disease for>3 months. Toxicities included an immune-mediated thrombocytopenia in one pa tient and Staphylococcus sepsis that was not associated with neutropenia in five patients. Pharmacokinetic parameters were determined b

Year: 2013
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • http://cancerres.aacrjournals.... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.